Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome.
Several liposomal formulations of anthracyclines have been developed recently and are currently used in the clinical setting. We describe a technique of separation and quantification of the liposomal and non-liposomal forms of daunorubicin in the plasma of patients treated with DaunoXome, a liposomal formulation of daunorubicin. The method we propose is based upon the property of liposomes to cross reversed-phase C18 silicagel cartridges without being retained, while non-liposomal drug is retained on the stationary phase and is eluted with methanol. Extraction of liposomal and non-liposomal daunorubicin from plasma, therefore, is performed in two steps. This technique is rapid, can be automated in order to handle large series of samples, and the plasma can be frozen after sampling by addition of glycerol. The recovery of liposomal daunorubicin as well as the precision, linearity and accuracy of the technique appear satisfactory for pharmacokinetic purposes.
Bellott
R
R
Institut Bergonié and Université Victor Segalen Bordeaux 2, France.
Pouna
P
P
Robert
J
J
D000903:Antibiotics, Antineoplastic / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002138:Calibration; D003630:Daunorubicin / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D015203:Reproducibility of Results
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin